BENEFITS

Healthcare practitioners will be able to instantly screen, assess, and monitor the neurocognitive functions of patients with suspected or confirmed neurological disorders or traumas.

Pharmaceutical companies will have access to a cognitive assessment tool that combines comprehensive research capabilities for testing drug effectiveness and dosaging with an efficient and affordable method of delivery and monitoring.

Researchers will have the capacity to conduct large-scale, standardized, longitudinal studies while contributing to and drawing from an enormous research database.